SCIENTIFIC PUBLICATIONS

COVID-19

Latest publication on the potential use of ET-traps for COVID-19. It should be noted that we have already established proof-of-concept both at the in vitro and in vivo levels in the diabetes disease space. And diabetics are at higher risk of a serious COVID-19 infection. This paper also fully discusses the merits of ET-traps as a potential therapeutic for the COVID-19 pandemic.

This article has been published in the Medicine in Drug Discovery, June 2020 Read more

Autoimmune diseases

New academic paper has been published in "Drug Discovery Today" entitled "ET-traps offer a potential therapeutic tool for use in different autoimmune diseases", April 2020 Read more.

Neurological disorders

Dr Arjun Jain's Review article - "ET-traps-a Novel Therapeutic for Treatment of Neurological Disorders" , 6 November, 2019. Read more

ET-traps: from diabetes to beyond

New academic paper has been published in "Drug Discovery Today" entitled "Endothelin-1 traps as a potential therapeutic tool: from diabetes to beyond?", September 2019. Read more

Animal studies on the efficacy of ET-traps for type-1 diabetes

New academic paper has been published in the "Journal of Diabetes & Metabolic Disorders " entitled " In vivo studies demonstrate that endothelin-1 traps are a potential therapy for type I diabetes".

In vitro studies on the efficacy of ET-traps for diabetes

Another publication pertaining to ET-traps was published in the "Journal of Diabetes & Metabolic Disorders " entitled "Endothelin-1 traps potently reduce pathologic markers back to basal levels in an in vitro model of diabetes".

1st in the world creation of a soluble form of a GPCR

Another publication by Dr. Arjun Jain pertaining to ET-traps was published in the "International Journal of Peptide Research and Therapeutics " entitled "Creating a soluble binder to endothelin-1 based on the natural ligand binding domains of the endothelin-1 (G-protein-coupled) receptor".